- This phase 4, randomized, double-blind study assessed the safety and the presence of antidrug antibodies (ADA) when receiving the liquid formulation of palivizumab compared with the lyophilized formulation.
- ADA were detected in 1 (0.5%) subject in the lyophilized palivizumab group (at 154 days post final dose) and no subjects in the liquid palivizumab group, with an overall percent positive of 0.3% for both treatment groups combined.
- The true ADA percent positive for both treatment groups combined based on the upper limit of the 95% confidence interval was <1.5%.
- The reported serious adverse events were consistent with common conditions in this pediatric age group and there was no evidence of an increase in respiratory syncytial virus disease with liquid palivizumab.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by MedImmune. Medical writing and editorial assistance, provided by John E. Fincke, PhD, and Anny Wu, PharmD, of Complete Healthcare Communications, Inc. (Chadds Ford, PA, USA), was supported by MedImmune. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.